The past week saw a powerful rollout of second quarter results from big cap biotechs. Amgen (AMGN), Celgene (CELG), Biogen Idec (BIIB), Gilead Sciences (GILD) and Regeneron Pharmaceutical (REGN) all topped analyst consensus views, plus raised their Q3 and full-year guidance. Amgen hit its highest point in almost seven years Friday. Alexion Pharmaceuticals (ALXN) smashed views, raised its outlook and surged 8% for the week. Vertex Pharmaceuticals